|
1
|
Cuenca-López MD, Montero JC, Morales JC,
Prat A, Pandiella A and Ocana A: Phospho-kinase profile of triple
negative breast cancer and androgen receptor signaling. BMC Cancer.
14:3022014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Craig DW, O'Shaughnessy JA, Kiefer JA,
Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A,
Blum JL, et al: Genome and transcriptome sequencing in prospective
metastatic triple-negative breast cancer uncovers therapeutic
vulnerabilities. Mol Cancer Ther. 12:104–116. 2013. View Article : Google Scholar
|
|
5
|
Pal SK, Childs BH and Pegram M: Triple
negative breast cancer: Unmet medical needs. Breast Cancer Res
Treat. 125:627–636. 2011. View Article : Google Scholar :
|
|
6
|
André F and Zielinski CC: Optimal
strategies for the treatment of metastatic triple-negative breast
cancer with currently approved agents. Ann Oncol. 23(Suppl 6):
vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lehmann BD and Pietenpol JA:
Identification and use of biomarkers in treatment strategies for
triple-negative breast cancer subtypes. J Pathol. 232:142–150.
2014. View Article : Google Scholar :
|
|
8
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dann SG, Selvaraj A and Thomas G: mTOR
Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and
cancer. Trends Mol Med. 13:252–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yaba A, Bianchi V, Borini A and Johnson J:
A putative mitotic checkpoint dependent on mTOR function controls
cell proliferation and survival in ovarian granulosa cells. Reprod
Sci. 15:128–138. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vazquez-Martin A, Oliveras-Ferraros C,
Bernadó L, López-Bonet E and Menendez JA: The serine
2481-autophosphorylated form of mammalian target of rapamycin
(mTOR) is localized to midzone and midbody in dividing cancer
cells. Biochem Biophys Res Commun. 380:638–643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walsh S, Flanagan L, Quinn C, Evoy D,
McDermott EW, Pierce A and Duffy MJ: mTOR in breast cancer:
Differential expression in triple-negative and non-triple-negative
tumors. Breast. 21:178–182. 2012. View Article : Google Scholar
|
|
13
|
Zhou X, Tan M, Stone Hawthorne V, Klos KS,
Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the
Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2
overexpression predicts tumor progression in breast cancers. Clin
Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueng SH, Chen SC, Chang YS, Hsueh S, Lin
YC, Chien HP, Lo YF, Shen SC and Hsueh C: Phosphorylated mTOR
expression correlates with poor outcome in early-stage triple
negative breast carcinomas. Int J Clin Exp Pathol. 5:806–813.
2012.PubMed/NCBI
|
|
15
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al American Society of Clinical Oncology; College
of American Pathologists: Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American Society
of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yunokawa M, Koizumi F, Kitamura Y,
Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M,
Masutomi K, et al: Efficacy of everolimus, a novel mTOR inhibitor,
against basal-like triple-negative breast cancer cells. Cancer Sci.
103:1665–1671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vazquez-Martin A, Oliveras-Ferraros C, Del
Barco S, Martin-Castillo B and Menendez JA: If mammalian target of
metformin indirectly is mammalian target of rapamycin, then the
insulin-like growth factor-1 receptor axis will audit the efficacy
of metformin in cancer clinical trials. J Clin Oncol. 27:e207–209;
author reply e210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Cohen AL, Krishnakumar S, Wapnir
IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M,
et al: Patient-derived xenografts of triple-negative breast cancer
reproduce molecular features of patient tumors and respond to mTOR
inhibition. Breast Cancer Res. 16:R362014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu S, Li S, Guo Z, Luo J, Ellis MJ and Ma
CX: Combined targeting of mTOR and AKT is an effective strategy for
basal-like breast cancer in patient-derived xenograft models. Mol
Cancer Ther. 12:1665–1675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bose S, Chandran S, Mirocha JM and Bose N:
The Akt pathway in human breast cancer: a tissue-array-based
analysis. Mod Pathol. 19:238–245. 2006. View Article : Google Scholar
|
|
23
|
Lehmann BD, Bauer JA, Schafer JM,
Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H,
Arteaga CL, et al: PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity to the combination
of PI3K and androgen receptor inhibitors. Breast Cancer Res.
16:4062014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gucalp A and Traina TA: Triple-negative
breast cancer: Role of the androgen receptor. Cancer J. 16:62–65.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Edlind MP and Hsieh AC: PI3K-AKT-mTOR
signaling in prostate cancer progression and androgen deprivation
therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong G, Liang X, Wang D, Gao H, Wang L,
Wang L, Liu J and Du Z: High expression of miR-21 in
triple-negative breast cancers was correlated with a poor prognosis
and promoted tumor cell in vitro proliferation. Med Oncol.
31:572014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Medimegh I, Omrane I, Privat M, Uhrhummer
N, Ayari H, Belaiba F, Benayed F, Benromdhan K, Mader S, Bignon IJ,
et al: MicroRNAs expression in triple negative vs non triple
negative breast cancer in Tunisia: Interaction with clinical
outcome. PLoS One. 9:e1118772014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang J, Dibble CC, Matsuzaki M and
Manning BD: The TSC1-TSC2 complex is required for proper activation
of mTOR complex 2. Mol Cell Biol. 28:4104–4115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
DeYoung MP, Horak P, Sofer A, Sgroi D and
Ellisen LW: Hypoxia regulates TSC1/2-mTOR signaling and tumor
suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev.
22:239–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Culjkovic B, Topisirovic I, Skrabanek L,
Ruiz-Gutierrez M and Borden KL: eIF4E is a central node of an RNA
regulon that governs cellular proliferation. J Cell Biol.
175:415–426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Culjkovic-Kraljacic B, Baguet A, Volpon L,
Amri A and Borden KL: The oncogene eIF4E reprograms the nuclear
pore complex to promote mRNA export and oncogenic transformation.
Cell Rep. 2:207–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Giulietti M, Milantoni SA, Armeni T,
Principato G and Piva F: ExportAid: Database of RNA elements
regulating nuclear RNA export in mammals. Bioinformatics.
31:246–251. 2015. View Article : Google Scholar
|
|
35
|
Rokavec M, Li H, Jiang L and Hermeking H:
The p53/miR-34 axis in development and disease. J Mol Cell Biol.
6:214–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hermeking H: MicroRNAs in the p53 network:
Micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Östling P, Leivonen SK, Aakula A, Kohonen
P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici
D, et al: Systematic analysis of microRNAs targeting the androgen
receptor in prostate cancer cells. Cancer Res. 71:1956–1967. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ribas J, Ni X, Haffner M, Wentzel EA,
Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J,
Rodriguez R, et al: miR-21: An androgen receptor-regulated microRNA
that promotes hormone-dependent and hormone-independent prostate
cancer growth. Cancer Res. 69:7165–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Teng Y, Litchfield LM, Ivanova MM, Prough
RA, Clark BJ and Klinge CM: Dehydroepiandrosterone-induces miR-21
transcription in HepG2 cells through estrogen receptor β and
androgen receptor. Mol Cell Endocrinol. 392:23–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma X, Choudhury SN, Hua X, Dai Z and Li Y:
Interaction of the oncogenic miR-21 microRNA and the p53 tumor
suppressor pathway. Carcinogenesis. 34:1216–1223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xiong Q, Zhong Q, Zhang J, Yang M, Li C,
Zheng P, Bi LJ and Ge F: Identification of novel miR-21 target
proteins in multiple myeloma cells by quantitative proteomics. J
Proteome Res. 11:2078–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bao B, Ali S, Kong D, Sarkar SH, Wang Z,
Banerjee S, Aboukameel A, Padhye S, Philip PA and Sarkar FH:
Anti-tumor activity of a novel compound-CDF is mediated by
regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS
One. 6:e178502011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Darido C, Georgy SR, Wilanowski T, Dworkin
S, Auden A, Zhao Q, Rank G, Srivastava S, Finlay MJ, Papenfuss AT,
et al: Targeting of the tumor suppressor GRHL3 by a
miR-21-dependent proto-oncogenic network results in PTEN loss and
tumorigenesis. Cancer Cell. 20:635–648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang H, Liu P, Yang L and Xie X, Ye F, Wu
M, Liu X, Chen B, Zhang L and Xie X: miR-185 suppresses tumor
proliferation by directly targeting E2F6 and DNMT1 and indirectly
upregulating BRCA1 in triple-negative breast cancer. Mol Cancer
Ther. 13:3185–3197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cascione L, Gasparini P, Lovat F, Carasi
S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, et
al: Integrated microRNA and mRNA signatures associated with
survival in triple negative breast cancer. PLoS One. 8:e559102013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Augoff K, McCue B, Plow EF and
Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are
regulated by promoter hypermethylation in triple-negative breast
cancer. Mol Cancer. 11:52012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Humphries B, Wang Z, Oom AL, Fisher T, Tan
D, Cui Y, Jiang Y and Yang C: MicroRNA-200b targets protein kinase
Cα and suppresses triple-negative breast cancer metastasis.
Carcinogenesis. 35:2254–2263. 2014. View Article : Google Scholar : PubMed/NCBI
|
